Listen
CIMZIA (certolizumab pegol), anti-TNF α
RHEUMATOLOGY - New indication
Opinions on drugs -
Posted on
Nov 03 2016
Reason for request
Extension of indication
Insufficient actual benefit in the treatment of rheumatoid arthritis in adults previously untreated with methotrexate or other disease-modifying treatments.
- CIMZIA, in combination with methotrexate (MTX), now has Marketing Authorisation in the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults previously untreated with MTX or other disease-modifying treatments.
- It is preferable, at an early stage, to await a response to the first line treatment with methotrexate with a dynamic therapeutic adaptation strategy and, if need be, to introduce a targeted treatment in the event of inadequate response to methotrexate or methotrexate intolerance.
- CIMZIA has no place in the treatment strategy of patients previously untreated with a conventional disease-modifying treatment, in particular MTX.
Clinical Benefit
| Insufficient |
- |
Clinical Added Value
| Not applicable |
- |
Therapeutic use
|
- |
English version
Contact Us
Évaluation des médicaments
